Silence Therapeutics (SLN) Total Current Liabilities (2018 - 2025)
Silence Therapeutics' Total Current Liabilities history spans 8 years, with the latest figure at $13.6 million for Q4 2025.
- On a quarterly basis, Total Current Liabilities fell 19.08% to $13.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.6 million, a 19.08% decrease, with the full-year FY2025 number at $13.6 million, down 19.08% from a year prior.
- Total Current Liabilities hit $13.6 million in Q4 2025 for Silence Therapeutics, down from $17.4 million in the prior quarter.
- Over the last five years, Total Current Liabilities for SLN hit a ceiling of $25.7 million in Q4 2022 and a floor of -$30.6 million in Q3 2022.
- Historically, Total Current Liabilities has averaged -$7.8 million across 5 years, with a median of -$21.1 million in 2022.
- Biggest five-year swings in Total Current Liabilities: plummeted 185.69% in 2023 and later soared 207.13% in 2025.
- Tracing SLN's Total Current Liabilities over 5 years: stood at $20.4 million in 2021, then increased by 25.89% to $25.7 million in 2022, then plummeted by 185.69% to -$22.1 million in 2023, then soared by 176.28% to $16.8 million in 2024, then decreased by 19.08% to $13.6 million in 2025.
- Business Quant data shows Total Current Liabilities for SLN at $13.6 million in Q4 2025, $17.4 million in Q3 2025, and $14.8 million in Q2 2025.